Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2018

View Archived Issues

Crinetics Pharmaceuticals awarded NIDDK grants

iTeos Therapeutics completes series B financing to support immuno-oncology programs

Biocad initiates phase I study of BCD-132 in patients with multiple sclerosis

First-in-human data presented for oncolytic virus Celyvir in solid tumors

Lilly's acquisition of ARMO BioSciences complete

Phase I results available for CUDC-907 in pediatric solid tumors

ARQ-531 demonstrates preliminary signs of antitumor activity in B-cell malignancies

AZD-9567 shows better therapeutic ratio than prednisolone in vivo and in clinical setting

FDA awards orphan drug designation to PCS-499 for necrobiosis lipoidica

Ohara Pharmaceutical obtains certain rights to compound from PRISM Pharma

City of Hope studies memory-enriched T cells in recurrent or refractory glioma

IMpower133 study of Tecentriq in extensive stage SCLC meets coprimary endpoints

Erytech refocuses development efforts with eryaspase

YH-25448 demonstrates promising antitumor activity in patients with EGFR T790M-positive NSCLC

Prefusion F protein respiratory syncytial virus vaccine DS-Cav1 safe in first-in-human study

FDA clears IND for pivotal trial of INP-104 for acute treatment of migraine

J-TEC signs license agreement for low-cost manufacturing technology of CAR-T cells

Cellenkos and University of Texas enter neuroinflammation research collaboration

DSMB of Aladote phase Ib/IIa study to treat paracetamol poisoning finds no safety concerns

Merrimack discontinues development of MM-141 for pancreatic cancer following CARRIE results

CellCentric initiates first-in-man study of CCS-1477 for late-stage prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...